Zhang Yong
Pulmonary Department, Fudan University Zhongshan Hospital, Shanghai, 200032 China.
Mol Cell Ther. 2014 Feb 1;2:4. doi: 10.1186/2052-8426-2-4. eCollection 2014.
Apixaban, a new oral inhibitor of activated factor Xa, may simplify antithrombotic therapy with fixed doses and no necessity for coagulation monitoring. Apixaban is non-inferior to conventional therapy (enxoaparin, followed by warfarin) with lower risk of major bleeding in the treatment of acute venous thromboembolism. Compared with placebo, extended treatment with apixaban may reduce the recurrence rate in patients with venous thromboembolism. Thromboprophylaxis therapy with apixaban in surgery (hip or knee replacement) and atrial fibrillation has been proved to be superior to warfarin or enxoaparin. Apixaban offers a convenient and more effective alternative choice in anticoagulant therapy.
阿哌沙班是一种新型的活化因子Xa口服抑制剂，它可能会简化抗血栓治疗，采用固定剂量且无需进行凝血监测。在治疗急性静脉血栓栓塞症时，阿哌沙班不劣于传统疗法（先使用依诺肝素，随后使用华法林），且大出血风险更低。与安慰剂相比，阿哌沙班延长治疗可能会降低静脉血栓栓塞症患者的复发率。已证实，在外科手术（髋关节或膝关节置换）和房颤中，阿哌沙班进行血栓预防治疗优于华法林或依诺肝素。阿哌沙班在抗凝治疗中提供了一种方便且更有效的替代选择。
